NCT00438217Unknown4 期
Analysis of Genetic and Environmental Parameters Influencing Growth Rate of Precocious Puberty Children
适应症
相关药物
试验速览
- 阶段
- 4 期
- 入组人数
- 100
- 试验地点
- 2
研究概览
简要总结
The goal of CPP-EDG 01 study is to assess possible genetic and/or environmental parameters which may influence the growth rate of children affected by precocious puberty. In this view, we are collecting clinical data and biological samples of children attended as outpatients at the Pediatric Endocrine Center of Pisa from 1998 to present (the study is still open). From biological (blood) samples, gene polymorphisms such as endocrine disruptor levels are determined and compared to different growth pattern of pediatric patients treated with different GnRH agonists.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 1 Year 至 18 Years(Child, Adult)
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Clinica diagnosis of central precocious puberty
- •Diagnosis is based on growth spurt, bone age advancement, positive GnRH agonist stimulating test, pubertal sex steroid levels before 8 years of age for female and 9 years for male, respectively
排除标准
- •Thyroid disorders
- •Peripheric diagnosis of precocious puberty
- •Genetic disorders
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
不适用
Genetic and Environmental Risk Factors of Type 1 Autoimmune Diabetes and Its Early ComplicationsInsulin-DependentDiabetes MellitusNCT02212522Assistance Publique - Hôpitaux de Paris20,000
Unknown
不适用
Identification of Genetic Factors Determining Disease Course in the New Type of Coronavirus Infection, COVID-19COVID-19Sars-CoV2NCT04426253Szeged University1,000
招募中
不适用
Identification of Risk Factors, Exposomics and Genetic Susceptibility of Melanoma in Children, Adolescents and Young AdultsSpitzoid MelanomaCongenital NeviMelanomaNCT06680323University Hospital Tuebingen200
招募中
不适用
Genes and Environment in Multiple SclerosisMultiple SclerosisNCT01353547Columbia University5,000
已完成
3 期
A Study of Genetic and Environmental Factors and Their Effect on Response to Treatment With Lucentis (Ranibizumab) for Wet AMDMacular DegenerationNCT00469352Oregon Health and Science University150
